{
    "4 17 2025": {
        "importantArticles": [
            {
                "headline": "Despite its expensive valuation, we suggest investors hold LLY stock as the company boasts solid growth prospects.",
                "publication_date": "2025-04-17T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.6597",
                "source": "Zacks",
                "ticker": "NVO",
                "title": "Eli Lilly Stock Down 8.2% in a Month: Should You Buy the Dip?",
                "url": "https://finance.yahoo.com/news/eli-lilly-stock-down-8-110500046.html"
            },
            {
                "headline": "We came across a bullish thesis on Novo Nordisk A/S (NVO) on Substack by Felix. In this article, we will summarize the bulls\u2019 thesis on NVO. Novo Nordisk A/S (NVO)\u2019s share was trading at $64.49 as of April 15th. NVO\u2019s trailing and forward P/E were 18.76 and 15.41 respectively according to Yahoo Finance. Novo Nordisk, a dominant [\u2026]",
                "publication_date": "2025-04-17T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.5574",
                "source": "Insider Monkey",
                "ticker": "NVO",
                "title": "Novo Nordisk A/S (NVO): A Bull Case Theory",
                "url": "https://finance.yahoo.com/news/novo-nordisk-nvo-bull-case-183735432.html"
            },
            {
                "headline": "Telehealth providers, whose revenue skyrocketed amidst GLP-1 shortages, remain defiant on their compounded semaglutide offerings.",
                "publication_date": "2025-04-17T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.3612",
                "source": "Pharmaceutical Technology",
                "ticker": "NVO",
                "title": "The GLP-1 drug shortage is over. What\u2019s next for the compounders?",
                "url": "https://finance.yahoo.com/news/glp-1-drug-shortage-over-143913812.html"
            },
            {
                "headline": "We recently published a list of Jim Cramer Discussed These 12 Stocks Recently. In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against other stocks that Jim Cramer discussed recently. On Friday, Mad Money host Jim Cramer addressed growing concerns in the market as tensions between the [\u2026]",
                "publication_date": "2025-04-17T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.6369",
                "source": "Insider Monkey",
                "ticker": "NVO",
                "title": "\u201cI Am a Buyer\u201d: Jim Cramer Backs Novo Nordisk (NVO) After Its Sharp Decline",
                "url": "https://finance.yahoo.com/news/am-buyer-jim-cramer-backs-020413895.html"
            },
            {
                "headline": "Telehealth providers, whose revenue skyrocketed amidst GLP-1 shortages, remain defiant on their compounded semaglutide offerings.",
                "publication_date": "2025-04-17T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.3612",
                "source": "Pharmaceutical Technology",
                "ticker": "NVO",
                "title": "The GLP-1 drug shortage is over. What\u2019s next for the compounders?",
                "url": "https://finance.yahoo.com/news/glp-1-drug-shortage-over-143913812.html"
            },
            {
                "headline": "We came across a bullish thesis on Novo Nordisk A/S (NVO) on Substack by Felix. In this article, we will summarize the bulls\u2019 thesis on NVO. Novo Nordisk A/S (NVO)\u2019s share was trading at $64.49 as of April 15th. NVO\u2019s trailing and forward P/E were 18.76 and 15.41 respectively according to Yahoo Finance. Novo Nordisk, a dominant [\u2026]",
                "publication_date": "2025-04-17T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.5574",
                "source": "Insider Monkey",
                "ticker": "NVO",
                "title": "Novo Nordisk A/S (NVO): A Bull Case Theory",
                "url": "https://finance.yahoo.com/news/novo-nordisk-nvo-bull-case-183735432.html"
            }
        ],
        "avgScore": 0.054749999999999965
    },
    "4 16 2025": {
        "importantArticles": [
            {
                "headline": "We recently published a list of 10 Best Pharma Stocks to Buy for Long Term Growth. In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against other best pharma stocks to buy for long term growth. U.S. Pharma Turns to China for Drug Deals With big American [\u2026]",
                "publication_date": "2025-04-16T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.9274",
                "source": "Insider Monkey",
                "ticker": "NVO",
                "title": "Is Novo Nordisk A/S (NVO) the Best Pharma Stock to Buy for Long Term Growth?",
                "url": "https://finance.yahoo.com/news/novo-nordisk-nvo-best-pharma-185200431.html"
            },
            {
                "headline": "Shares of Novo Nordisk, Eli Lilly, Structure Therapeutics and Viking Therapeutics gain as PFE abandons development of its obesity candidate, danuglipron, due to safety issues.",
                "publication_date": "2025-04-16T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.7269",
                "source": "Zacks",
                "ticker": "NVO",
                "title": "NVO, LLY, GPCR & VKTX Stocks Gain Following PFE's Obesity Study Setback",
                "url": "https://finance.yahoo.com/news/nvo-lly-gpcr-vktx-stocks-140000975.html"
            },
            {
                "headline": "Shares of Viking Therapeutics (VKTX) and Structure Therapeutics (GPCR) are on the rise on Monday after Pfizer (PFE) announced its decision to discontinue development of danuglipron, an oral glucagon-like peptide-1 receptor agonist, which was being investigated for chronic weight management. While Morgan Stanley predicts \u201climited reaction\u201d in Pfizer\u2019s shares following the news, JPMorgan tells investors that the decision is \u201cmostly a positive\u201d for Structure and Viking, both developing drugs in the",
                "publication_date": "2025-04-16T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.5267",
                "source": "TipRanks",
                "ticker": "NVO",
                "title": "Smaller obesity drugmakers jump after Pfizer scraps weight-loss pill",
                "url": "https://finance.yahoo.com/news/smaller-obesity-drugmakers-jump-pfizer-143525028.html"
            },
            {
                "headline": "PFE's decision to scrap the development of danuglipron comes after a study participant develops potential drug-induced liver injury.",
                "publication_date": "2025-04-16T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.4215",
                "source": "Zacks",
                "ticker": "NVO",
                "title": "Pfizer Halts Obesity Pill Development Amid Safety Concerns",
                "url": "https://finance.yahoo.com/news/pfizer-halts-obesity-pill-development-165700605.html"
            },
            {
                "headline": "On Monday, Novo Nordisk A/S (NYSE:NVO) said it had become aware of several hundred units of Ozempic (semaglutide) injection 1 mg distributed outside the Novo Nordisk authorized supply chain in the U.S. The seized counterfeit products feature lot number PAR0362 and illegitimate serial numbers beginning with the first eight digits 51746517. Lot number PAR0362 is an authentic lot number. Only when the lot number is coupled with the eight digits 51746517 it is counterfeit and should not be used. Als",
                "publication_date": "2025-04-16T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.296",
                "source": "Benzinga",
                "ticker": "NVO",
                "title": "Counterfeit Ozempic Identified in US Supply Chain With Fake Labels And Needles, FDA Alerts",
                "url": "https://finance.yahoo.com/news/counterfeit-ozempic-identified-us-supply-202035878.html"
            },
            {
                "headline": "Shares of Viking Therapeutics (VKTX) and Structure Therapeutics (GPCR) are on the rise on Monday after Pfizer (PFE) announced its decision to discontinue development of danuglipron, an oral glucagon-like peptide-1 receptor agonist, which was being investigated for chronic weight management. While Morgan Stanley predicts \u201climited reaction\u201d in Pfizer\u2019s shares following the news, JPMorgan tells investors that the decision is \u201cmostly a positive\u201d for Structure and Viking, both developing drugs in the",
                "publication_date": "2025-04-16T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.5267",
                "source": "TipRanks",
                "ticker": "NVO",
                "title": "Smaller obesity drugmakers jump after Pfizer scraps weight-loss pill",
                "url": "https://finance.yahoo.com/news/smaller-obesity-drugmakers-jump-pfizer-143525028.html"
            }
        ],
        "avgScore": 0.41109999999999997
    },
    "4 15 2025": {
        "importantArticles": [
            {
                "headline": "HYDERABAD (Reuters) -The India launch of Eli Lilly's popular weight-loss drug Mounjaro has triggered a huge wave of patient enquiries about its availability, with some Indian doctors fielding hundreds of calls about the medicine, according to a Reuters survey.  The survey of 18 doctors, patients and weight-loss clinic operators follows the U.S. drugmaker's market entry ahead of Danish obesity drug rival Novo Nordisk into a nation expected to have the second-largest population of overweight or obese people by 2050.  \"Since the launch of Mounjaro, we have seen a remarkable increase in customer interest,\" said Suryansh Kumar, founder of  Delhi-based weight management services provider Elevate Now.",
                "publication_date": "2025-04-15T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.8176",
                "source": "Reuters",
                "ticker": "NVO",
                "title": "Eli Lilly's Mounjaro launch in India ignites wave of weight-loss enquiries",
                "url": "https://finance.yahoo.com/news/eli-lillys-mounjaro-launch-india-194918761.html"
            },
            {
                "headline": "The global demographic shift is reshaping healthcare demand, driving long-term investment in pharmaceuticals, medical devices, home care and digital health.",
                "publication_date": "2025-04-15T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.4019",
                "source": "Zacks",
                "ticker": "NVO",
                "title": "Tap Into the Silver Economy Boom With These Aging Demographics Stocks",
                "url": "https://finance.yahoo.com/news/tap-silver-economy-boom-aging-190000247.html"
            },
            {
                "headline": "Pfizer ends its most advanced clinical trial of an obesity pill to compete in the hot GLP-1 space.",
                "publication_date": "2025-04-15T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.3167",
                "source": "Yahoo Finance",
                "ticker": "NVO",
                "title": "Pfizer discontinues GLP-1 pill trial, stock trades flat",
                "url": "https://finance.yahoo.com/news/pfizer-discontinues-glp-1-pill-trial-stock-trades-flat-135330797.html"
            },
            {
                "headline": "Pfizer (PFE) announced Monday that it is ending development of its daily weight-loss pill following a liver injury to a patient participating in a trial.",
                "publication_date": "2025-04-15T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.4215",
                "source": "Quartz",
                "ticker": "NVO",
                "title": "Pfizer just had a big setback in its race for an Ozempic competitor",
                "url": "https://finance.yahoo.com/news/pfizer-just-had-big-setback-145553640.html"
            },
            {
                "headline": "Pfizer said it will stop development of an oral weight-loss pill after a participant taking the drug in a clinical trial experienced a \"liver injury.\"",
                "publication_date": "2025-04-15T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.296",
                "source": "Investopedia",
                "ticker": "NVO",
                "title": "Pfizer Halts Development of Obesity Drug After Patient Sustains 'Liver Injury'",
                "url": "https://finance.yahoo.com/news/pfizer-halts-development-obesity-drug-141357676.html"
            },
            {
                "headline": "Pfizer bows, but is not entirely out of the GLP-1 race.",
                "publication_date": "2025-04-15T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Motley Fool",
                "ticker": "NVO",
                "title": "Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Popped Today",
                "url": "https://finance.yahoo.com/news/why-eli-lilly-novo-nordisk-151230600.html"
            }
        ],
        "avgScore": 0.13645
    },
    "4 11 2025": {
        "importantArticles": [
            {
                "headline": "Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.",
                "publication_date": "2025-04-11T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.4215",
                "source": "Zacks",
                "ticker": "NVO",
                "title": "These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar",
                "url": "https://finance.yahoo.com/news/2-medical-stocks-could-beat-130011780.html"
            },
            {
                "headline": "Procter & Gamble, Novo Nordisk, PepsiCo, Genie Energy and Canterbury Park are included in this Analyst Blog.",
                "publication_date": "2025-04-11T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.2732",
                "source": "Zacks",
                "ticker": "NVO",
                "title": "The Zacks Analyst Blog Highlights Procter & Gamble, Novo Nordisk, PepsiCo, Genie Energy and Canterbury Park",
                "url": "https://finance.yahoo.com/news/zacks-analyst-blog-highlights-procter-090000606.html"
            },
            {
                "headline": "Robert F. Kennedy Jr. is the new Health Secretary. From fluoride, vaccines and beef tallow, here's how he might \"go wild\" on biotech stocks.",
                "publication_date": "2025-04-11T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Investor's Business Daily",
                "ticker": "NVO",
                "title": "Trump Wants RFK Jr. To 'Go Wild' On Health Care. What This Means For Biotech Stocks.",
                "url": "https://finance.yahoo.com/m/ad410584-ce11-3244-a597-6a1760bc9030/trump-wants-rfk-jr-to-go.html"
            },
            {
                "headline": "The tariff war has prompted new calls to reshore manufacturing. Several large pharmas have already made the leap.",
                "publication_date": "2025-04-11T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.5994",
                "source": "Pharma Voice",
                "ticker": "NVO",
                "title": "Pharma\u2019s US manufacturing moment: Where companies are making the biggest moves",
                "url": "https://finance.yahoo.com/news/pharma-manufacturing-moment-where-companies-071322162.html"
            },
            {
                "headline": "The news of a likely import tariff hurt the share price of pharma giants like Novo Nordisk (NVO), Eli Lilly (LLY) and AstraZeneca (AZN), but Trump's announcement of a pause on reciprocal tariffs offsets the losses.",
                "publication_date": "2025-04-11T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.5267",
                "source": "Zacks",
                "ticker": "NVO",
                "title": "Pharma Stocks Rebound as Trump Announces a 90-Day Pause on Tariffs",
                "url": "https://finance.yahoo.com/news/pharma-stocks-rebound-trump-announces-125400968.html"
            },
            {
                "headline": "The latest investor updates on stocks that are trending on Thursday.",
                "publication_date": "2025-04-11T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Yahoo Finance UK",
                "ticker": "NVO",
                "title": "Trending tickers: TSMC, Trump Media, US Steel, Novo Nordisk and Tesco",
                "url": "https://finance.yahoo.com/news/tsmc-trump-media-us-steel-novo-nordisk-tesco-trending-tickers-094532440.html"
            }
        ],
        "avgScore": -0.0719
    },
    "4 10 2025": {
        "importantArticles": [
            {
                "headline": "Equity markets may be struggling because of President Donald Trump's current economic policies, but that doesn't mean investors should avoid buying stocks right now -- quite the contrary.  History tells us that equities tend to experience strong runs following downturns, so it's worth putting money into excellent companies that are being dragged down with along with the broader market.  To that end, let's consider five excellent growth-oriented companies to invest in on the dip: Novo Nordisk (NYSE: NVO), Eli Lilly (NYSE: LLY), Vertex Pharmaceuticals (NASDAQ: VRTX), Intuitive Surgical (NASDAQ: ISRG), and Shopify (NASDAQ: SHOP).",
                "publication_date": "2025-04-10T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.9362",
                "source": "Motley Fool",
                "ticker": "NVO",
                "title": "5 Top Growth Stocks to Buy in the Stock Market Sell-Off",
                "url": "https://finance.yahoo.com/news/5-top-growth-stocks-buy-140000326.html"
            },
            {
                "headline": "Today's Research Daily features new research reports on 16 major stocks, including The Procter & Gamble Company (PG), Novo Nordisk A/S (NVO) and PepsiCo, Inc. (PEP), as well as two micro-cap stocks Genie Energy Ltd. (GNE) and Canterbury Park Holding Corporation (CPHC).",
                "publication_date": "2025-04-10T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.4939",
                "source": "Zacks",
                "ticker": "NVO",
                "title": "Top Analyst Reports for Procter & Gamble, Novo Nordisk & PepsiCo",
                "url": "https://finance.yahoo.com/news/top-analyst-reports-procter-gamble-205100046.html"
            },
            {
                "headline": "Pharma names whipsawed Wednesday after Trump said he would enact \"major\" tariffs on drug imports and then backed off his tariffs \u2014 for now.",
                "publication_date": "2025-04-10T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0258",
                "source": "Investor's Business Daily",
                "ticker": "NVO",
                "title": "Dow Jones, S&P 500 Pharma Names Recover After Trump Backs Off His Tariffs Plan",
                "url": "https://finance.yahoo.com/m/be7d1b24-7c1e-38ff-91b2-281ea7807568/dow-jones-s-p-500-pharma.html"
            },
            {
                "headline": "Stocks in drugmakers sold off globally after President Trump said tariffs on pharmaceutical imports will be unveiled shortly, signaling the industry could be next in line amid a trade war that is causing market turmoil.  AbbVie, Eli Lilly, Johnson & Johnson, Merck and Pfizer were all down at least 2.5% in Wednesday midday trading.  Denmark's Novo Nordisk, Switzerland's Novartis and the U.K.'s AstraZeneca and GSK fell 2% or more in the U.S.",
                "publication_date": "2025-04-10T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.7506",
                "source": "The Wall Street Journal",
                "ticker": "NVO",
                "title": "Novo Nordisk, AbbVie Stocks Slide After Trump Vows Pharma Tariffs",
                "url": "https://finance.yahoo.com/m/f171bfb7-94e2-3b98-bde2-9d5add357a5c/novo-nordisk-abbvie-stocks.html"
            },
            {
                "headline": "Catalysts host Madison Mills goes over some of the top stories of the day on this segment of Market Minute. Delta Air Lines (DAL) cut its full-year guidance as uncertainty around tariffs weighs on bookings. Walmart (WMT) walks back its first quarter profit guidance, citing tariff risks. Pharmaceutical stocks, including Pfizer (PFE), Novo Nordisk (NVO), and Eli Lilly (LLY), are under pressure after President Trump announced that there may be pharmaceutical tariffs underway. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.",
                "publication_date": "2025-04-10T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.4767",
                "source": "Yahoo Finance Video",
                "ticker": "NVO",
                "title": "Delta, Walmart, pharmaceutical stocks: Market Minute",
                "url": "https://finance.yahoo.com/video/delta-walmart-pharmaceutical-stocks-market-151538726.html"
            },
            {
                "headline": "The latest investor updates on stocks that are trending on Wednesday.",
                "publication_date": "2025-04-10T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Yahoo Finance UK",
                "ticker": "NVO",
                "title": "Trending tickers: Apple, Advanced Micro Devices, Ford, BP and AstraZeneca",
                "url": "https://finance.yahoo.com/news/apple-advanced-micro-devices-ford-bp-astrazeneca-trending-tickers-093254195.html"
            }
        ],
        "avgScore": 0.03265714285714284
    },
    "4 9 2025": {
        "importantArticles": [
            {
                "headline": "Both LLY and NVO are leading pharmaceutical companies specializing in diabetes and obesity treatments.",
                "publication_date": "2025-04-09T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Zacks",
                "ticker": "NVO",
                "title": "LLY vs. NVO: Which Weight-Loss Drug Stock is a Stronger Play Now?",
                "url": "https://finance.yahoo.com/news/lly-vs-nvo-weight-loss-140900571.html"
            },
            {
                "headline": "Novo Nordisk (NVO) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
                "publication_date": "2025-04-09T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.1621",
                "source": "Zacks",
                "ticker": "NVO",
                "title": "Novo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on It",
                "url": "https://finance.yahoo.com/news/novo-nordisk-nvo-trending-stock-130012251.html"
            },
            {
                "headline": "Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by the comments, actions and policies of President Donald Trump with this daily recap compiled by The Fly: TRUMP SAYS NO INFLATION: President Trump said via Truth Social, \u201cOil prices are down, interest rates are down (the slow moving Fed should cut rates!), food prices are down, there is NO INFLATION, and the long time abused USA is bringing in Billions of Dollars a week from the abusing countries on",
                "publication_date": "2025-04-09T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.8155",
                "source": "TipRanks",
                "ticker": "NVO",
                "title": "Trump Trade: Trump claims \u2018no inflation,\u2019 Medicare won\u2019t cover obesity drugs",
                "url": "https://finance.yahoo.com/news/trump-trade-trump-claims-no-142755841.html"
            },
            {
                "headline": "Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by the comments, actions and policies of President Donald Trump with this daily recap compiled by The Fly: TRUMP SAYS NO INFLATION: President Trump said via Truth Social, \u201cOil prices are down, interest rates are down (the slow moving Fed should cut rates!), food prices are down, there is NO INFLATION, and the long time abused USA is bringing in Billions of Dollars a week from the abusing countries on",
                "publication_date": "2025-04-09T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.8155",
                "source": "TipRanks",
                "ticker": "NVO",
                "title": "Trump Trade: Trump claims \u2018no inflation,\u2019 Medicare won\u2019t cover obesity drugs",
                "url": "https://finance.yahoo.com/news/trump-trade-trump-claims-no-142755841.html"
            },
            {
                "headline": "Novo Nordisk (NVO) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
                "publication_date": "2025-04-09T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.1621",
                "source": "Zacks",
                "ticker": "NVO",
                "title": "Novo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on It",
                "url": "https://finance.yahoo.com/news/novo-nordisk-nvo-trending-stock-130012251.html"
            },
            {
                "headline": "Both LLY and NVO are leading pharmaceutical companies specializing in diabetes and obesity treatments.",
                "publication_date": "2025-04-09T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Zacks",
                "ticker": "NVO",
                "title": "LLY vs. NVO: Which Weight-Loss Drug Stock is a Stronger Play Now?",
                "url": "https://finance.yahoo.com/news/lly-vs-nvo-weight-loss-140900571.html"
            }
        ],
        "avgScore": -0.3258666666666667
    },
    "4 8 2025": {
        "importantArticles": [
            {
                "headline": "Danish drugmaker Novo Nordisk is looking at an early launch of its blockbuster weight-loss drug Wegovy in India to better compete with rival Eli Lilly in the populous nation, two sources familiar with the plans told Reuters.  Novo, which had earlier planned for a 2026 launch of the drug, is now looking to begin selling Wegovy in India \"this year, probably in the next few months,\" sources told Reuters on condition of anonymity as they were not authorized to talk to the media.",
                "publication_date": "2025-04-08T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.7783",
                "source": "Reuters",
                "ticker": "NVO",
                "title": "Novo preparing for early launch of weight-loss drug Wegovy in India",
                "url": "https://finance.yahoo.com/news/novo-preparing-early-launch-weight-152952920.html"
            },
            {
                "headline": "This decision is a blow for Eli Lilly and Novo Nordisk, who had both previously endorsed the proposed expansion.",
                "publication_date": "2025-04-08T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.25",
                "source": "Pharmaceutical Technology",
                "ticker": "NVO",
                "title": "Obesity drugs won\u2019t be covered by Medicare under 2026 CMS policy",
                "url": "https://finance.yahoo.com/news/obesity-drugs-won-t-covered-111330060.html"
            },
            {
                "headline": "The decision is a setback for GLP-1 drugmakers, though it's not entirely surprising given the Trump administration\u2019s focus on curbing government spending.",
                "publication_date": "2025-04-08T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.2572",
                "source": "Healthcare Dive",
                "ticker": "NVO",
                "title": "Trump rejects Biden administration plan to let Medicare cover obesity drugs",
                "url": "https://finance.yahoo.com/news/trump-rejects-biden-administration-plan-095500389.html"
            },
            {
                "headline": "CMS keeps out LLY and NVO's obesity drugs from Medicare coverage. Medicare, at present, does not cover obesity drugs if they are solely prescribed for weight loss.",
                "publication_date": "2025-04-08T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.3182",
                "source": "Zacks",
                "ticker": "NVO",
                "title": "NVO & LLY Shares Down on Exclusion of Obesity Drugs From Medicare",
                "url": "https://finance.yahoo.com/news/nvo-lly-shares-down-exclusion-131400783.html"
            },
            {
                "headline": "The weight-loss drug war is heating up--and Novo just made its boldest move yet deep in Latin America.",
                "publication_date": "2025-04-08T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.3182",
                "source": "GuruFocus.com",
                "ticker": "NVO",
                "title": "Novo Nordisk's $1B Power Play: Can Brazil Make or Break the Ozempic Empire?",
                "url": "https://finance.yahoo.com/news/novo-nordisks-1b-power-play-201720029.html"
            },
            {
                "headline": "The decision is a setback for GLP-1 drugmakers, though it's not entirely surprising given the Trump administration\u2019s focus on curbing government spending.",
                "publication_date": "2025-04-08T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.2572",
                "source": "Healthcare Dive",
                "ticker": "NVO",
                "title": "Trump rejects Biden administration plan to let Medicare cover obesity drugs",
                "url": "https://finance.yahoo.com/news/trump-rejects-biden-administration-plan-095500389.html"
            }
        ],
        "avgScore": 0.02694000000000001
    },
    "4 4 2025": {
        "importantArticles": [
            {
                "headline": "Artisan Partners, an investment management company, released its \u201cArtisan Global Opportunities Fund\u201d fourth quarter 2024 investor letter. A copy of the letter can be downloaded here. US equities experienced significant gains in Q4, showcasing a strong year. The portfolio showed slight weakness in Q4 but posted a strong absolute return in 2024. In the fourth [\u2026]",
                "publication_date": "2025-04-04T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.8225",
                "source": "Insider Monkey",
                "ticker": "NVO",
                "title": "Artisan Global Opportunities Fund Trimmed its Position in Novo Nordisk A/S (NVO)",
                "url": "https://finance.yahoo.com/news/artisan-global-opportunities-fund-trimmed-114310970.html"
            },
            {
                "headline": "Novo Nordisk (NVO) closed at $67.10 in the latest trading session, marking a -1.67% move from the prior day.",
                "publication_date": "2025-04-04T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Zacks",
                "ticker": "NVO",
                "title": "Novo Nordisk (NVO) Stock Moves -1.67%: What You Should Know",
                "url": "https://finance.yahoo.com/news/novo-nordisk-nvo-stock-moves-214514258.html"
            },
            {
                "headline": "Novo Holdings, the controlling shareholder of weight loss drugmaker Novo Nordisk A/S (NYSE:NVO), reported Wednesday income and investment returns of 60 billion Danish kroner (around $8.68 billion) for 2024. Novo Holdings owns 28.1% shares in Novo ...",
                "publication_date": "2025-04-04T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "-0.0258",
                "source": "Benzinga",
                "ticker": "NVO",
                "title": "Novo Nordisk Stakeholder Reports $9 Billion In Income Due To Robust Weight Loss Drug Sales",
                "url": "https://finance.yahoo.com/news/novo-nordisk-stakeholder-reports-9-013028787.html"
            },
            {
                "headline": "Novo Holdings, the controlling shareholder of weight loss drugmaker Novo Nordisk A/S (NYSE:NVO), reported Wednesday income and investment returns of 60 billion Danish kroner (around $8.68 billion) for 2024. Novo Holdings owns 28.1% shares in Novo ...",
                "publication_date": "2025-04-04T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "-0.0258",
                "source": "Benzinga",
                "ticker": "NVO",
                "title": "Novo Nordisk Stakeholder Reports $9 Billion In Income Due To Robust Weight Loss Drug Sales",
                "url": "https://finance.yahoo.com/news/novo-nordisk-stakeholder-reports-9-013028787.html"
            },
            {
                "headline": "Novo Nordisk (NVO) closed at $67.10 in the latest trading session, marking a -1.67% move from the prior day.",
                "publication_date": "2025-04-04T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Zacks",
                "ticker": "NVO",
                "title": "Novo Nordisk (NVO) Stock Moves -1.67%: What You Should Know",
                "url": "https://finance.yahoo.com/news/novo-nordisk-nvo-stock-moves-214514258.html"
            },
            {
                "headline": "Artisan Partners, an investment management company, released its \u201cArtisan Global Opportunities Fund\u201d fourth quarter 2024 investor letter. A copy of the letter can be downloaded here. US equities experienced significant gains in Q4, showcasing a strong year. The portfolio showed slight weakness in Q4 but posted a strong absolute return in 2024. In the fourth [\u2026]",
                "publication_date": "2025-04-04T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.8225",
                "source": "Insider Monkey",
                "ticker": "NVO",
                "title": "Artisan Global Opportunities Fund Trimmed its Position in Novo Nordisk A/S (NVO)",
                "url": "https://finance.yahoo.com/news/artisan-global-opportunities-fund-trimmed-114310970.html"
            }
        ],
        "avgScore": 0.2655666666666667
    },
    "4 3 2025": {
        "importantArticles": [
            {
                "headline": "Drugmakers breathed a sigh of relief Wednesday after President Trump didn\u2019t announce pharmaceutical tariffs.  Plus, language in the executive order indicated medicines were exempted from the reciprocal tariffs that Trump did announce.  Drugmakers were combing over the executive order to clarify the exemption language in the executive order and to make sure they won\u2019t be hit by any other tariff provisions, such as the 10% \u201cbaseline\u201d tariff.",
                "publication_date": "2025-04-03T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.6705",
                "source": "The Wall Street Journal",
                "ticker": "NVO",
                "title": "Big Pharma Avoids Worst-Case Tariff Scenario",
                "url": "https://finance.yahoo.com/m/06d142db-a905-336a-a0df-f505312c37de/big-pharma-avoids-worst-case.html"
            },
            {
                "headline": "The upside comes after Lexicon lands a deal worth $1 billion for its experimental obesity drug with Novo Nordisk.",
                "publication_date": "2025-04-03T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.2263",
                "source": "Zacks",
                "ticker": "NVO",
                "title": "LXRX Stock Moves Up 30% in a Week: What is Driving This Rally?",
                "url": "https://finance.yahoo.com/news/lxrx-stock-moves-30-week-141800883.html"
            },
            {
                "headline": "Novo Holdings, the controlling shareholder of Ozempic-maker Novo Nordisk (NVO), nearly doubled its annual income and investment returns in 2024.",
                "publication_date": "2025-04-03T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Quartz",
                "ticker": "NVO",
                "title": "Novo Holdings' earnings nearly doubled in 2024, despite Novo Nordisk's stock slump",
                "url": "https://finance.yahoo.com/news/novo-holdings-earnings-nearly-doubled-151300670.html"
            },
            {
                "headline": "Hims stock clawed higher Wednesday though analysts laid out low expectations for Him & Hers' branded tirzepatide.",
                "publication_date": "2025-04-03T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.2732",
                "source": "Investor's Business Daily",
                "ticker": "NVO",
                "title": "Hims Claws Back After Its Lilly-Rivaling Obesity Plan Faces An Unexpected Hitch",
                "url": "https://finance.yahoo.com/m/0a24e75b-02ee-3b96-9b67-944a285506f5/hims-claws-back-after-its.html"
            },
            {
                "headline": "Bagsv\u00e6rd, Denmark, 3 April 2025 \u2013 Novo Nordisk today announced the following changes in Executive Management. After a distinguished career of 28 years with Novo Nordisk, hereof seven years as executive vice president of Commercial Strategy & Corporate Affairs, Camilla Sylvest has decided to leave the company. Consequently, as of 3 April 2025, the following organisational changes are implemented: Ludovic Helfgott, executive vice president, Rare Disease, will assume the responsibility for Product",
                "publication_date": "2025-04-03T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.0516",
                "source": "GlobeNewswire",
                "ticker": "NVO",
                "title": "Novo Nordisk announces changes in Executive Management",
                "url": "https://finance.yahoo.com/news/novo-nordisk-announces-changes-executive-060000828.html"
            },
            {
                "headline": "Novo Nordisk's head of commercial strategy and corporate affairs, Camilla Sylvest, has decided to leave the company, the Danish drugmaker said on Thursday. Novo's rare disease unit head, Ludovic Helfgott, who was already on the executive management team, will immediately assume the responsibility for product and portfolio strategy, including commercial strategy, medical affairs and business development across all therapy areas, the company said. Sylvest was one of two women on Novo's 10-person executive management team.",
                "publication_date": "2025-04-03T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.0516",
                "source": "Reuters",
                "ticker": "NVO",
                "title": "Novo Nordisk's head of commercial strategy steps down",
                "url": "https://finance.yahoo.com/news/novo-nordisks-head-commercial-strategy-063544371.html"
            }
        ],
        "avgScore": 0.08673333333333334
    },
    "4 2 2025": {
        "importantArticles": [
            {
                "headline": "Telehealth firm Hims & Hers Health said on Tuesday it plans to sell Eli Lilly's weight-loss drug, as it widens its offerings to offset any impact from impending restrictions on selling copies of Novo Nordisk's obesity drug.  Shares of Hims & Hers closed 5.1% higher after the company said it will expand its weight-loss offerings with branded versions of Lilly's tirzepatide \u2014 the active ingredient in weight-loss drug Zepbound and diabetes medicine Mounjaro \u2014 and generics of Novo's diabetes drug, liraglutide.",
                "publication_date": "2025-04-02T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.7351",
                "source": "Reuters",
                "ticker": "NVO",
                "title": "Hims & Hers to sell Lilly's weight-loss drug on its telehealth platform",
                "url": "https://finance.yahoo.com/news/hims-hers-sell-lillys-weight-173933173.html"
            },
            {
                "headline": "The company has a looming opportunity to grab the booming GLP-1 agonist market by the horns.",
                "publication_date": "2025-04-02T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.3182",
                "source": "Motley Fool",
                "ticker": "NVO",
                "title": "Where Will Eli Lilly Be in 1 Year?",
                "url": "https://finance.yahoo.com/news/where-eli-lilly-1-093700057.html"
            },
            {
                "headline": "Hims stock surged Tuesday after the compounding pharmacy said it would sell Eli Lilly's branded weight-loss drug on its telehealth platform.",
                "publication_date": "2025-04-02T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Investor's Business Daily",
                "ticker": "NVO",
                "title": "Hims Stock Jumps After Adding Eli Lilly's Obesity Drug To Its Platform",
                "url": "https://finance.yahoo.com/m/877a443d-016e-3f73-9182-44a3661c599e/hims-stock-jumps-after-adding.html"
            },
            {
                "headline": "Investing.com -- Barclays has lowered its first-quarter 2025 estimates for Novo Nordisk (CSE:NOVOb) (NYSE:NVO) ahead of its Q1 2025 report, citing weaker-than-expected prescription volumes for key drugs Wegovy and Ozempic in the U.S.",
                "publication_date": "2025-04-02T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.128",
                "source": "Investing.com",
                "ticker": "NVO",
                "title": "Barclays cuts Novo Nordisk estimates on lower Wegovy, Ozempic volumes in the U.S.",
                "url": "https://finance.yahoo.com/news/barclays-cuts-novo-nordisk-estimates-140717529.html"
            },
            {
                "headline": "Hims stock surged Tuesday after the compounding pharmacy said it would sell Eli Lilly's branded weight-loss drug on its telehealth platform.",
                "publication_date": "2025-04-02T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Investor's Business Daily",
                "ticker": "NVO",
                "title": "Hims Stock Jumps After Adding Eli Lilly's Obesity Drug To Its Platform",
                "url": "https://finance.yahoo.com/m/877a443d-016e-3f73-9182-44a3661c599e/hims-stock-jumps-after-adding.html"
            },
            {
                "headline": "The company has a looming opportunity to grab the booming GLP-1 agonist market by the horns.",
                "publication_date": "2025-04-02T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.3182",
                "source": "Motley Fool",
                "ticker": "NVO",
                "title": "Where Will Eli Lilly Be in 1 Year?",
                "url": "https://finance.yahoo.com/news/where-eli-lilly-1-093700057.html"
            }
        ],
        "avgScore": 0.23132499999999998
    },
    "4 1 2025": {
        "importantArticles": [
            {
                "headline": "DexCom's recent licensing deal with Nanowear is likely to reinforce the broader potential of CGMs in continuous metabolic health monitoring.",
                "publication_date": "2025-04-01T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Zacks",
                "ticker": "NVO",
                "title": "DXCM Inks Deal With Nanowear to Boost CGM Application Beyond Diabetes",
                "url": "https://finance.yahoo.com/news/dxcm-inks-deal-nanowear-boost-133000845.html"
            },
            {
                "headline": "(Bloomberg) -- As Novo Nordisk A/S shares head for their worst month in more than two decades, the days when the Danish drugmaker was valued at more than $600 billion are becoming a distant memory.Most Read from BloombergGold-Rush Fever Returns to Historic New Zealand Mining TownWhat Frank Lloyd Wright Learned From the DesertBank Regulators Fight for Desks as OCC Returns to New York TowerThese US Bridges Face High Risk of Catastrophic Ship StrikesCharter Schools, Colleges Push Muni Debt Distress",
                "publication_date": "2025-04-01T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.9153",
                "source": "Bloomberg",
                "ticker": "NVO",
                "title": "Novo Nordisk\u2019s Worst Month Since 2002 Shows Growth Concerns",
                "url": "https://finance.yahoo.com/news/novo-nordisk-worst-month-since-101148181.html"
            },
            {
                "headline": "(Bloomberg) -- As Novo Nordisk A/S shares head for their worst month in more than two decades, the days when the Danish drugmaker was valued at more than $600 billion are becoming a distant memory.Most Read from BloombergGold-Rush Fever Returns to Historic New Zealand Mining TownWhat Frank Lloyd Wright Learned From the DesertBank Regulators Fight for Desks as OCC Returns to New York TowerThese US Bridges Face High Risk of Catastrophic Ship StrikesCharter Schools, Colleges Push Muni Debt Distress",
                "publication_date": "2025-04-01T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.9153",
                "source": "Bloomberg",
                "ticker": "NVO",
                "title": "Novo Nordisk\u2019s Worst Month Since 2002 Shows Growth Concerns",
                "url": "https://finance.yahoo.com/news/novo-nordisk-worst-month-since-101148181.html"
            },
            {
                "headline": "DexCom's recent licensing deal with Nanowear is likely to reinforce the broader potential of CGMs in continuous metabolic health monitoring.",
                "publication_date": "2025-04-01T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Zacks",
                "ticker": "NVO",
                "title": "DXCM Inks Deal With Nanowear to Boost CGM Application Beyond Diabetes",
                "url": "https://finance.yahoo.com/news/dxcm-inks-deal-nanowear-boost-133000845.html"
            }
        ],
        "avgScore": -0.45765
    },
    "3 31 2025": {
        "importantArticles": [
            {
                "headline": "The two market leaders are targeting new obesity alternatives in their pipelines with an eye toward a triple threat.",
                "publication_date": "2025-03-31T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.5267",
                "source": "Pharma Voice",
                "ticker": "NVO",
                "title": "In the obesity triple-agonist blockbuster race, a familiar battle looms: Novo vs. Lilly",
                "url": "https://finance.yahoo.com/news/obesity-triple-agonist-blockbuster-race-072319136.html"
            },
            {
                "headline": "The two market leaders are targeting new obesity alternatives in their pipelines with an eye toward a triple threat.",
                "publication_date": "2025-03-31T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.5267",
                "source": "Pharma Voice",
                "ticker": "NVO",
                "title": "In the obesity triple-agonist blockbuster race, a familiar battle looms: Novo vs. Lilly",
                "url": "https://finance.yahoo.com/news/obesity-triple-agonist-blockbuster-race-072319136.html"
            }
        ],
        "avgScore": -0.5267
    },
    "3 28 2025": {
        "importantArticles": [
            {
                "headline": "This might surprise some, but Danish pharmaceutical giant Novo Nordisk (NYSE: NVO) has significantly lagged the market in the past year.  The drugmaker's shares are down by 40% over the trailing-12-month period, despite grabbing headlines for its work in the red-hot weight management drug market.  Novo Nordisk has faced some issues, but even taking those into account, the company's prospects remain excellent.",
                "publication_date": "2025-03-28T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.8555",
                "source": "Motley Fool",
                "ticker": "NVO",
                "title": "1 Growth Stock Down 40% to Buy and Hold Forever",
                "url": "https://finance.yahoo.com/news/1-growth-stock-down-40-140000868.html"
            },
            {
                "headline": "Novo Nordisk's (NYSE: NVO) is famous and celebrated for its cutting-edge obesity medication.  Its U.S.-traded American depositary receipts (ADRs) saw their price slump by more than 2% following the move, a steeper decline than the S&P 500 index's 0.3% slip.  Well before market open that morning, Morgan Stanley's Thibault Boutherin knocked his Novo Nordisk price target down to 600 Danish kroner ($86.67) per share; previously, this number was 700 kroner ($101.11).",
                "publication_date": "2025-03-28T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.8074",
                "source": "Motley Fool",
                "ticker": "NVO",
                "title": "Why Novo Nordisk Stock Dipped on Thursday",
                "url": "https://finance.yahoo.com/news/why-novo-nordisk-stock-dipped-223600186.html"
            },
            {
                "headline": "Bagsv\u00e6rd, Denmark, 27 March 2025 - Today, Novo Nordisk A/S held its Annual General Meeting. At the Annual General Meeting, Helge Lund, chair of the Board of Directors communicated: \u201c2024 was another year of significant growth for Novo Nordisk, characterised by continued innovation, capacity expansions and commercial execution. Our industry-leading therapeutic innovations benefited more than 45 million people living with diabetes and obesity worldwide. As we strive to keep pace with increasing de",
                "publication_date": "2025-03-28T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.7184",
                "source": "GlobeNewswire",
                "ticker": "NVO",
                "title": "Resolutions from the Annual General Meeting of Novo Nordisk A/S",
                "url": "https://finance.yahoo.com/news/resolutions-annual-general-meeting-novo-151700469.html"
            },
            {
                "headline": "LONDON (Reuters) -Novo Nordisk shares have fallen 25% so far in March and are on track for their biggest monthly drop since July 2002, as investor worries intensify that the obesity drug market pioneer has lost its edge over U.S. rival Eli Lilly.  Novo came under pressure last year to prove it could keep its advantage in the lucrative obesity market after U.S. rival Lilly launched its own injection Zepbound, which led in clinical trials to greater weight loss than Wegovy.  That has not happened, say investors and analysts observing rapidly worsening market sentiment toward Novo, despite the fact that Wegovy sales more than doubled in the fourth quarter of last year.",
                "publication_date": "2025-03-28T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.8402",
                "source": "Reuters",
                "ticker": "NVO",
                "title": "Novo shares on track for biggest monthly fall since 2002, investor worries grow",
                "url": "https://finance.yahoo.com/news/novo-shares-track-biggest-monthly-172918460.html"
            },
            {
                "headline": "Sales of Novo Nordisk\u2019s (NVO) blockbuster weight-loss drug Wegovy took a hit due to rising competition from off-brand, or compounded, versions of the treatment, according to the Danish pharma giant\u2019s CEO Lars Fruergaard J\u00f8rgensen.",
                "publication_date": "2025-03-28T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.5994",
                "source": "Quartz",
                "ticker": "NVO",
                "title": "Wegovy sales took a hit this year. Novo's CEO blames off-brand competition",
                "url": "https://finance.yahoo.com/news/wegovy-sales-took-hit-novos-210400146.html"
            },
            {
                "headline": "Bagsv\u00e6rd, Denmark, 27 March 2025 - Today, Novo Nordisk A/S held its Annual General Meeting. At the Annual General Meeting, Helge Lund, chair of the Board of Directors communicated: \u201c2024 was another year of significant growth for Novo Nordisk, characterised by continued innovation, capacity expansions and commercial execution. Our industry-leading therapeutic innovations benefited more than 45 million people living with diabetes and obesity worldwide. As we strive to keep pace with increasing de",
                "publication_date": "2025-03-28T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.7184",
                "source": "GlobeNewswire",
                "ticker": "NVO",
                "title": "Resolutions from the Annual General Meeting of Novo Nordisk A/S",
                "url": "https://finance.yahoo.com/news/resolutions-annual-general-meeting-novo-151700469.html"
            }
        ],
        "avgScore": 0.42810000000000004
    },
    "3 27 2025": {
        "importantArticles": [
            {
                "headline": "The German firm licensed a PRMT5 inhibitor that\u2019s now in Phase 1 testing. Elsewhere, GSK is testing an intriguing hypothesis and Novo fine tuned its Wegovy cash-pay program.",
                "publication_date": "2025-03-27T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.128",
                "source": "BioPharma Dive",
                "ticker": "NVO",
                "title": "Bayer gains cancer drug from China\u2019s Puhe; Axsome gets mixed ADHD data",
                "url": "https://finance.yahoo.com/news/bayer-gains-cancer-drug-china-113000028.html"
            },
            {
                "headline": "Cigna (CI) CEO David Cordani is not convinced of the benefits of GLP-1s for weight-loss patients and said the US is the only country among developed nations where insurance coverage is being debated.",
                "publication_date": "2025-03-27T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.088",
                "source": "Yahoo Finance",
                "ticker": "NVO",
                "title": "US is only country debating GLP-1 insurance coverage for weight loss: Cigna CEO Cordani",
                "url": "https://finance.yahoo.com/news/us-is-only-country-debating-glp-1-insurance-coverage-for-weight-loss-cigna-ceo-cordani-201308049.html"
            },
            {
                "headline": "The latest investor updates on stocks that are trending on Wednesday.",
                "publication_date": "2025-03-27T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Yahoo Finance UK",
                "ticker": "NVO",
                "title": "Trending tickers: GameStop, UPS, Trump Media, Nissan and Vistry",
                "url": "https://finance.yahoo.com/news/gamestop-ups-trump-media-nissan-vistry-trending-tickers-120457754.html"
            },
            {
                "headline": "MRK in-licenses an experimental lipoprotein(a) inhibitor from China's Jiangsu Hengrui. This transaction is expected to be closed in the second quarter of 2025.",
                "publication_date": "2025-03-27T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.0772",
                "source": "Zacks",
                "ticker": "NVO",
                "title": "Merck Inks $2B Licensing Deal With Chinese Biotech for Oral Heart Drug",
                "url": "https://finance.yahoo.com/news/merck-inks-2b-licensing-deal-121700157.html"
            },
            {
                "headline": "Novo Nordisk leads a GLP-1 agonist market that could surpass $150 billion by 2035. Ironically, the market is passing on the stock right now. Should you?",
                "publication_date": "2025-03-27T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Motley Fool",
                "ticker": "NVO",
                "title": "Is Novo Nordisk Stock a Buy?",
                "url": "https://finance.yahoo.com/news/novo-nordisk-stock-buy-091300557.html"
            },
            {
                "headline": "The latest investor updates on stocks that are trending on Wednesday.",
                "publication_date": "2025-03-27T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Yahoo Finance UK",
                "ticker": "NVO",
                "title": "Trending tickers: GameStop, UPS, Trump Media, Nissan and Vistry",
                "url": "https://finance.yahoo.com/news/gamestop-ups-trump-media-nissan-vistry-trending-tickers-120457754.html"
            }
        ],
        "avgScore": 0.027759999999999996
    },
    "3 26 2025": {
        "importantArticles": [
            {
                "headline": "Tesla bounces back amid autonomous driving hope, United Airlines hikes card and lounge fees, and more news to start your day.",
                "publication_date": "2025-03-26T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.6908",
                "source": "Barrons.com",
                "ticker": "NVO",
                "title": "Trump Tariff Uncertainty Will Break This Stock Market Calm, Brace for Another Storm. And 5 Other Things to Know Today.",
                "url": "https://finance.yahoo.com/m/608e6048-cc3e-3e5e-b7a0-b5e5acd98639/trump-tariff-uncertainty-will.html"
            },
            {
                "headline": "R&D innovation is likely to remain a major focus area in 2025. In the Large-Cap Pharmaceuticals industry, AbbVie (ABBV), Novo Nordisk (NVO), Novartis (NVS), Pfizer (PFE) and Bayer (BAYRY) are worth retaining in one's portfolio",
                "publication_date": "2025-03-26T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.5423",
                "source": "Zacks",
                "ticker": "NVO",
                "title": "5 Large Drug Stocks to Watch as Industry Recovers",
                "url": "https://finance.yahoo.com/news/5-large-drug-stocks-watch-104700001.html"
            },
            {
                "headline": "Big Pharma is expected to see big returns from its investment in a class of drugs made famous by Novo Nordisk\u2019s (NVO) popular diabetes drug Ozempic.",
                "publication_date": "2025-03-26T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.4215",
                "source": "Quartz",
                "ticker": "NVO",
                "title": "GLP-1s are driving returns on R&D investments for Big Pharma, report says",
                "url": "https://finance.yahoo.com/news/glp-1s-driving-returns-r-182600084.html"
            },
            {
                "headline": "Novo Nordisk is making plans for a Wegovy successor amid uncertainty surrounding CagriSema.",
                "publication_date": "2025-03-26T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.128",
                "source": "Pharmaceutical Technology",
                "ticker": "NVO",
                "title": "Novo Nordisk earmarks $2bn for Chinese \u201ctriple G\u201d weight loss shot",
                "url": "https://finance.yahoo.com/news/novo-nordisk-earmarks-2bn-chinese-160148892.html"
            },
            {
                "headline": "The two stocks have been trending in different directions for months. Here's what that says about the broader market.",
                "publication_date": "2025-03-26T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Barrons.com",
                "ticker": "NVO",
                "title": "Step Aside, Novo Nordisk. This Is Europe\u2019s No. 1 Company Now.",
                "url": "https://finance.yahoo.com/m/f583370e-141b-3b9f-bcad-d0f91dcc042a/step-aside-novo-nordisk-.html"
            },
            {
                "headline": "NVO's shares are down 2% despite making Wegovy available at a discounted price of $499 per month at local pharmacies.",
                "publication_date": "2025-03-26T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.34",
                "source": "Zacks",
                "ticker": "NVO",
                "title": "Novo Nordisk Expands Wegovy Price Cut Program, Stock Still Falls 2%",
                "url": "https://finance.yahoo.com/news/novo-nordisk-expands-wegovy-price-160400232.html"
            }
        ],
        "avgScore": 0.3111
    },
    "3 25 2025": {
        "importantArticles": [
            {
                "headline": "We recently published a list of 11 Best Extremely Profitable Stocks to Buy According to Analysts. In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against other best extremely profitable stocks to buy according to analysts. Fed\u2019s Response to Inflation and Growth Challenges We recently covered 10 Best [\u2026]",
                "publication_date": "2025-03-25T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.9715",
                "source": "Insider Monkey",
                "ticker": "NVO",
                "title": "Is Novo Nordisk A/S (NYSE:NVO) The Best Extremely Profitable Stocks to Buy According to Analyst?",
                "url": "https://finance.yahoo.com/news/novo-nordisk-nyse-nvo-best-034219868.html"
            },
            {
                "headline": "(Reuters) -Danish drugmaker Novo Nordisk has bought global rights to China-based United Laboratories International's so-called \"triple-G\" weight-loss drug candidate in a deal worth up to $2 billion.  Novo has been trying to strengthen its foothold in the potential $150 billion obesity market through the development of next-generation drugs, acquisitions and partnerships.  With the United Lab deal, it has gained the rights to develop, manufacture and sell its experimental drug, UBT251.",
                "publication_date": "2025-03-25T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.886",
                "source": "Reuters",
                "ticker": "NVO",
                "title": "Novo bets on 'triple G' obesity drug in up to $2 billion deal with Chinese biotech",
                "url": "https://finance.yahoo.com/news/novo-licenses-chinese-biotechs-obesity-102141800.html"
            },
            {
                "headline": "Guangdong, China and Bagsv\u00e6rd, Denmark, 24 March 2025 \u2013The United Laboratories International Holdings Limited (TUL) and Novo Nordisk A/S (Novo Nordisk) today announced that Novo Nordisk and TUL\u2019s wholly-owned subsidiary The United Bio-Technology (Hengqin) Co., Ltd. (United Biotechnology), have entered into an exclusive license agreement for UBT251, a triple agonist of the receptors for GLP-1, GIP, and glucagon in early-stage clinical development for the treatment of obesity, type 2 diabetes, and",
                "publication_date": "2025-03-25T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.8126",
                "source": "GlobeNewswire",
                "ticker": "NVO",
                "title": "The United Laboratories and Novo Nordisk announce exclusive license agreement for UBT251, a GLP-1/GIP/glucagon triple receptor agonist",
                "url": "https://finance.yahoo.com/news/united-laboratories-novo-nordisk-announce-100200123.html"
            },
            {
                "headline": "There's a price war brewing in GLP-1 weight loss drugs, and now it's going global.",
                "publication_date": "2025-03-25T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.7351",
                "source": "Motley Fool",
                "ticker": "NVO",
                "title": "Why Novo Nordisk Stock Dropped on Monday, but Eli Lilly and Him & Hers Health Popped",
                "url": "https://finance.yahoo.com/news/why-novo-nordisk-stock-dropped-164401958.html"
            },
            {
                "headline": "(Bloomberg) -- German software developer SAP SE unseated Danish weight-loss drug maker Novo Nordisk A/S as Europe\u2019s most-valuable public company.Most Read from BloombergThey Built a Secret Apartment in a Mall. Now the Mall Is Dying.Chicago Transit Faces \u2018Doomsday Scenario,\u2019 Regional Agency SaysLA Faces $1 Billion Budget Hole, Warns of Thousands of LayoffsNew York Subway Ditches MetroCard After 32 Years for Tap-And-GoLibraries Warn They Could Be \u2018Cut off at the Knees\u2019 by DOGEShares of SAP, which",
                "publication_date": "2025-03-25T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.2023",
                "source": "Bloomberg",
                "ticker": "NVO",
                "title": "SAP Topples Novo to Become Europe\u2019s Biggest Listed Company",
                "url": "https://finance.yahoo.com/news/sap-topples-novo-become-europe-081430615.html"
            },
            {
                "headline": "German software company SAP overtook Danish healthcare company Novo Nordisk as Europe's largest company by market capitalisation on Monday. At 0900 GMT, SAP had a market cap of $340 billion, slightly more than Novo Nordisk, according to Reuters calculations using LSEG Workspace data. SAP is Europe's largest software maker, providing business application software used by companies for finance, sales, supply chain and other functions.",
                "publication_date": "2025-03-25T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Reuters",
                "ticker": "NVO",
                "title": "Software maker SAP unseats Novo Nordisk as Europe's largest company",
                "url": "https://finance.yahoo.com/news/germanys-sap-overtakes-novo-nordisk-092027677.html"
            }
        ],
        "avgScore": 0.3462333333333333
    },
    "3 21 2025": {
        "importantArticles": [
            {
                "headline": "Novo Nordisk (NVO) reachead $78.79 at the closing of the latest trading day, reflecting a -0.27% change compared to its last close.",
                "publication_date": "2025-03-21T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Zacks",
                "ticker": "NVO",
                "title": "Why Novo Nordisk (NVO) Dipped More Than Broader Market Today",
                "url": "https://finance.yahoo.com/news/why-novo-nordisk-nvo-dipped-214517794.html"
            },
            {
                "headline": "Novo Nordisk (NVO) reachead $78.79 at the closing of the latest trading day, reflecting a -0.27% change compared to its last close.",
                "publication_date": "2025-03-21T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Zacks",
                "ticker": "NVO",
                "title": "Why Novo Nordisk (NVO) Dipped More Than Broader Market Today",
                "url": "https://finance.yahoo.com/news/why-novo-nordisk-nvo-dipped-214517794.html"
            }
        ],
        "avgScore": 0.0
    },
    "3 20 2025": {
        "importantArticles": [
            {
                "headline": "Burke Wealth Management, an investment management company, released its \u201cFocused Growth Strategy\u201d fourth quarter 2024 investor letter. A copy of the letter can be downloaded here. The market had another outstanding year in 2024, with the S&P 500 rising 25.0%. The strategy had an even better year, with net returns of 28.4%. Looking a bit [\u2026]",
                "publication_date": "2025-03-20T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.9136",
                "source": "Insider Monkey",
                "ticker": "NVO",
                "title": "Novo Nordisk A/S (NVO) Traded Lower Due To Investor Disappointment Over Its New Drug In Obesity",
                "url": "https://finance.yahoo.com/news/novo-nordisk-nvo-traded-lower-134726126.html"
            },
            {
                "headline": "HYDERABAD (Reuters) -Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk for a much-awaited entry into the world's most populous country grappling with increasing rates of obesity and diabetes.  U.S.-based Lilly and Danish Novo Nordisk have seen skyrocketing global demand for their innovative weight-loss drugs, with investor interest also boosting the drugmakers' valuations.  Mounjaro, a once-weekly injection approved by India's drug regulator, is priced at 4,375 rupees ($50.67) for a 5 mg vial and 3,500 rupees ($40.54) for a 2.5 mg vial, its lowest doses, the company told Reuters exclusively.",
                "publication_date": "2025-03-20T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.8555",
                "source": "Reuters",
                "ticker": "NVO",
                "title": "Eli Lilly launches weight-loss drug Mounjaro in India, beats Novo Nordisk to major market",
                "url": "https://finance.yahoo.com/news/eli-lilly-launches-weight-loss-065417424.html"
            },
            {
                "headline": "According to the average brokerage recommendation (ABR), one should invest in Novo Nordisk (NVO). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?",
                "publication_date": "2025-03-20T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.743",
                "source": "Zacks",
                "ticker": "NVO",
                "title": "Novo Nordisk (NVO) Is Considered a Good Investment by Brokers: Is That True?",
                "url": "https://finance.yahoo.com/news/novo-nordisk-nvo-considered-good-133009533.html"
            },
            {
                "headline": "Build and maintain your watch list with the latest news and analysis of the market's top-rated growth stocks.",
                "publication_date": "2025-03-20T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.3818",
                "source": "Investor's Business Daily",
                "ticker": "NVO",
                "title": "Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks",
                "url": "https://finance.yahoo.com/m/6c5668d6-05c3-37a6-8af6-c6146e6b299b/stocks-to-buy-and-watch-top.html"
            },
            {
                "headline": "Polen Capital, an investment management company, released its \u201cPolen Global Growth Strategy\u201d fourth-quarter 2024 investor letter. A copy of the letter can be downloaded here. Over the past two years, global equities (2023-2024) showed a historic +45% cumulative return as per the MSCI ACWI Index (the \u201cIndex\u201d), emphasizing market unpredictability and the futility of macroeconomic [\u2026]",
                "publication_date": "2025-03-20T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.3818",
                "source": "Insider Monkey",
                "ticker": "NVO",
                "title": "Novo Nordisk A/S (NVO) Dropped as Trial Results Fell Short of Expectations",
                "url": "https://finance.yahoo.com/news/novo-nordisk-nvo-dropped-trial-130916376.html"
            },
            {
                "headline": "Investors weigh what's next for the market, searching for signals that the sell-off has either hit a bottom or has further to fall. Marketgauge.com chief strategist Michele Schneider joins Morning Brief to explain her \"vanity trade\" strategy, and says the consumer sector is a \"better barometer\" for investors to monitor than mega-cap names like Nvidia (NVDA). To watch more expert insights and analysis on the latest market action, check out more Morning Brief here.",
                "publication_date": "2025-03-20T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.5423",
                "source": "Yahoo Finance Video",
                "ticker": "NVO",
                "title": "Consumer sector is a 'better barometer' than Nvidia",
                "url": "https://finance.yahoo.com/video/consumer-sector-better-barometer-nvidia-100047823.html"
            }
        ],
        "avgScore": 0.6363333333333333
    },
    "3 19 2025": {
        "importantArticles": [
            {
                "headline": "We recently published a list of 10 Best Diabetes Stocks To Buy According to Billionaires. In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against other best diabetes stocks to buy according to billionaires. The Growing Market and Innovation in Continuous Glucose Monitoring (CGM) Technology The WHO [\u2026]",
                "publication_date": "2025-03-19T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.9136",
                "source": "Insider Monkey",
                "ticker": "NVO",
                "title": "Novo Nordisk (NVO): Among the Best Diabetes Stocks to Buy According to Billionaires",
                "url": "https://finance.yahoo.com/news/novo-nordisk-nvo-among-best-174539698.html"
            },
            {
                "headline": "This week\u2019s picks cover: Why Novo Nordisk will continue to dominate, how Nike's new DTC focus will restart growth, and why Rheinmetall is well positioned for Europe's remilitarization.",
                "publication_date": "2025-03-19T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.4939",
                "source": "Simply Wall St.",
                "ticker": "NVO",
                "title": "Weekly Picks: \ud83d\udc8a Novo Nordisk\u2019s breakout, Nike\u2019s reinvention, and Rheinmetall's opportunity",
                "url": "https://finance.yahoo.com/news/weekly-picks-novo-nordisk-breakout-034024656.html"
            },
            {
                "headline": "The consensus price target hints at a 44.2% upside potential for Novo Nordisk (NVO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.",
                "publication_date": "2025-03-19T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.4228",
                "source": "Zacks",
                "ticker": "NVO",
                "title": "Wall Street Analysts Predict a 44.2% Upside in Novo Nordisk (NVO): Here's  What You Should Know",
                "url": "https://finance.yahoo.com/news/wall-street-analysts-predict-44-135505999.html"
            },
            {
                "headline": "On Monday, Novo Nordisk A/S (NYSE:NVO) returned to full membership of the Association of the British Pharmaceutical Industry (ABPI) following extensive audits of the Wegovy maker's compliance procedures and governance by the Prescription Medicines Code of Practice Authority (PMCPA). The Association of the British Pharmaceutical Industry is the trade association for over 120 companies in the U.K. In March 2023, the ABPI Board decided to suspend Novo Nordisk from membership of the ABPI for two yea",
                "publication_date": "2025-03-19T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.25",
                "source": "Benzinga",
                "ticker": "NVO",
                "title": "UK Pharma Industry Trade Association Restores Wegovy/Ozempic Maker Novo Nordisk's Membership After 2 Years Of Suspension",
                "url": "https://finance.yahoo.com/news/uk-pharma-industry-trade-association-213025087.html"
            },
            {
                "headline": "We recently published a list of 10 Stocks Market Experts are Talking About These Days. In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against other stocks that market experts are talking about these days. Piper Sandler\u2019s Chief Market Technician Craig Johnson said in a latest program [\u2026]",
                "publication_date": "2025-03-19T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Insider Monkey",
                "ticker": "NVO",
                "title": "Novo Nordisk (NVO) to be \u2018Market Leader\u2019 Despite \u2018Horrifying\u2019 Declines",
                "url": "https://finance.yahoo.com/news/novo-nordisk-nvo-market-leader-220522109.html"
            },
            {
                "headline": "Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.",
                "publication_date": "2025-03-19T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.2732",
                "source": "Zacks",
                "ticker": "NVO",
                "title": "Why Novo Nordisk (NVO) is a Top Value Stock for the Long-Term",
                "url": "https://finance.yahoo.com/news/why-novo-nordisk-nvo-top-134011102.html"
            }
        ],
        "avgScore": 0.32500000000000007
    },
    "coef": -0.24035087719298245,
    "avgCoef": 0.01215808833720168,
    "similar": {
        "CMCSA": 0.3245614035087719,
        "UMC": 0.21228070175438596,
        "T": 0.18596491228070175,
        "PBR": 0.15438596491228068
    }
}